SLFN11 and cancer: A lack of SLFN11 expression renders a variety of cancers resistant to certain DDAs, as was demonstrated for topoisomerase I and II inhibitors, alkylating agents, and DNA synthesis inhibitors (e.g., gemcitabine) [35].